- Home
- ACLX vs VRNS Comparison
ACLX vs VRNS Comparison
Compare ACLX & VRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACLX
- VRNS
- Stock Information
- Founded
- ACLX 2015
- VRNS 2004
- Country
- ACLX United States
- VRNS United States
- Employees
- ACLX N/A
- VRNS N/A
- Industry
- ACLX Biotechnology: Pharmaceutical Preparations
- VRNS Computer Software: Prepackaged Software
- Sector
- ACLX Health Care
- VRNS Technology
- Exchange
- ACLX Nasdaq
- VRNS Nasdaq
- Market Cap
- ACLX 5.3B
- VRNS 5.6B
- IPO Year
- ACLX 2022
- VRNS 2014
- Fundamental
- Price
- ACLX $78.90
- VRNS $45.36
- Analyst Decision
- ACLX Strong Buy
- VRNS Buy
- Analyst Count
- ACLX 14
- VRNS 17
- Target Price
- ACLX $107.67
- VRNS $58.88
- AVG Volume (30 Days)
- ACLX 599.1K
- VRNS 1.4M
- Earning Date
- ACLX 11-07-2024
- VRNS 02-03-2025
- Dividend Yield
- ACLX N/A
- VRNS N/A
- EPS Growth
- ACLX N/A
- VRNS N/A
- EPS
- ACLX N/A
- VRNS N/A
- Revenue
- ACLX $155,818,000.00
- VRNS $546,535,000.00
- Revenue This Year
- ACLX $12.58
- VRNS $14.01
- Revenue Next Year
- ACLX N/A
- VRNS $11.79
- P/E Ratio
- ACLX N/A
- VRNS N/A
- Revenue Growth
- ACLX 230.33
- VRNS 12.07
- 52 Week Low
- ACLX $47.88
- VRNS $41.13
- 52 Week High
- ACLX $107.37
- VRNS $60.58
- Technical
- Relative Strength Index (RSI)
- ACLX 40.06
- VRNS 27.96
- Support Level
- ACLX $73.39
- VRNS $44.24
- Resistance Level
- ACLX $90.23
- VRNS $50.69
- Average True Range (ATR)
- ACLX 4.31
- VRNS 1.21
- MACD
- ACLX -0.60
- VRNS -0.14
- Stochastic Oscillator
- ACLX 27.75
- VRNS 17.21
About ACLX Arcellx Inc.
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
About VRNS Varonis Systems Inc.
Varonis Systems is a cybersecurity vendor focused on data privacy and security. The firm is currently undergoing a cloud transition as it weans its on-premises customers over to its cloud products that are delivered as software-as-a-service. The New York-based firm was founded in 2005 and went public in 2014.